Project Grant R01HL152201

This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $744,145 in funding to Vanderbilt University to develop a new class of antiarrhythmic agents that normalize dysfunctional RYR2 calcium release channels in the sarcoplasmic reticulum. The overarching goal is to select antiarrhythmic clinical candidates based on ent-verticilide, a potent inhibitor of RYR2-mediated calcium release in cardiomyocytes. The...

The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $684,937 project grant to The University of Iowa to investigate the role of the junctophilin-1 (JP1) protein in heart function and its potential as a therapeutic target for heart failure. The research aims to dissect the function of JP1, which is expressed in cardiac muscle, in order to elucidate its contribution to normal cardiac excitation-contraction coupling...

This federal Project Grant award of $131,571 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to improve the trafficking and function of the Kv11.1 potassium ion channel, which is implicated in cases of Long QT Syndrome (LQTS). The primary objectives are to 1) test the drug candidate evacetrapib for its ability to improve trafficking of LQTS-causing Kv11.1 variants, and 2) identify other targetable Kv11.1 protein interactions that could...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $865,286 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (d/b/a Boston Children's Hospital) to develop a high-resolution spatiotemporal lineage map of cardiac development. The project aims to: 1) spatiotemporally map early cardiac progenitor lineages and their clonal relationships, 2) spatiotemporally map the phylogeny of major myocardial cell types, and 3) define...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $195,000.00 to investigate the cellular mechanisms by which Long QT Syndrome-associated KCNH2 variants disrupt neuronal function. The award aims to use neurons differentiated from gene-edited and patient-derived human stem cells to determine how LQTS2-associated KCNH2 variants...

This Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to better understand the drivers and therapeutic targets for severe forms of arrhythmogenic cardiomyopathy (ARVD/C). The $727,710 award to the University of California, San Diego (UC San Diego) will support the development and study of preclinical mouse models of ARVD/C to investigate the role of inflammation and T cell...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $732,221 to The Johns Hopkins University to evaluate the clinical feasibility and safety of an mRNA-based biological pacemaker approach. The goal is to develop an alternative to implantable cardiac pacemakers by reprogramming ventricular myocytes to function as pacemaker cells, creating de novo cardiac pacing in vivo. The 4-year...

The National Heart, Lung, and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program, awarded a $2,095,748 Project Grant to Velakor Biotherapeutics, Inc. to conduct pre-clinical studies on the efficacy and dosing of CAM-6019, an innovative therapy designed to protect cardiac tissue, reduce adverse remodeling, and enable cardiac regeneration. The project aims to advance this potential regenerative treatment for heart failure, a leading cause of mortality...

This Project Grant award of $313,302 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel lead delivery platform to precisely identify and safely deliver cardiac conduction system (CCS) pacing leads. The awardee, Aust Development LLC, aims to create a 3D pre-shaped delivery catheter with a feature to enable physicians to monitor pacing parameters, implant depth and CCS capture while...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Northwestern University provides $601,612 to develop a novel, fully implantable device for high-definition mapping and therapy of paroxysmal atrial fibrillation (AF). The project aims to create a human-scale, organ-conformal electronics system that can painlessly detect and rapidly convert AF to normal sinus rhythm using optimized multi-pulse therapy. Key...